• Maribel Rodríguez-Torres.
• Fundación de Investigación, Ave. Muñoz Rivera #998, Río Piedras, PR 00927, USA +1 787 722 1248 +1 787 721 6098 mrodrigueztorres@fdipr.com.
• Expert Rev Anti Infect Ther. 2013 Dec 1; 11 (12): 1269-79.

AbstractGiven the global importance of chronic hepatitis C virus infection as a major health burden, there is still a need for treatment options that are more efficient, safer, simpler, more convenient and preferably interferon-free. Sofosbuvir (GS-7977; formerly PSI-7977) is a direct-acting antiviral agent that has met many of these attributes. This novel nucleotide analogue has demonstrated a consistently potent antiviral activity across several hepatitis C virus genotypes, and has been found to be safe and well tolerated when administered alone or with ribavarin +/- pegylated interferon. The clinical data evaluating the safety, tolerability and antiviral activity of sofosbuvir in various treatment regimens are presented in this article. Sofosbuvir is a major breakthrough in the care of HCV infection, making it possible that thousands of HCV infected patients around the world achieve cures, and preventing HCV associated morbidity and mortality.

31 keywords...

hide…